{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:54:50Z","timestamp":1781740490033,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","radiographyonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiography"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.radi.2026.103357","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:57:48Z","timestamp":1771336668000},"page":"103357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimising on-treatment review schedules: A narrative review of acute toxicities in ultra-hypofractionated stereotactic ablative body radiotherapy (SABR) for localised prostate cancer"],"prefix":"10.1016","volume":"32","author":[{"given":"G.","family":"McKenna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2428-6707","authenticated-orcid":false,"given":"T.","family":"Flood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radi.2026.103357_bib1","series-title":"About prostate cancer","year":"2025"},{"key":"10.1016\/j.radi.2026.103357_bib3","series-title":"Prostate cancer: diagnosis and management","year":"2021"},{"key":"10.1016\/j.radi.2026.103357_bib4","article-title":"Acute and late toxicity patterns of moderate hypo-fractionated radiotherapy for prostate cancer: a systematic review and meta-analysis","volume":"40","author":"Sinzabakira","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"issue":"7","key":"10.1016\/j.radi.2026.103357_bib5","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/1878-0261.12750","article-title":"Prevention and treatment of radiotherapy-induced side effects","volume":"14","author":"Barazzuol","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.radi.2026.103357_bib6","series-title":"Radiotherapy: general information for patients receiving treatment","year":"2023"},{"key":"10.1016\/j.radi.2026.103357_bib7","series-title":"Patient journey","year":"2025"},{"key":"10.1016\/j.radi.2026.103357_bib8","series-title":"Prostate cancer. Radiotherapy dose fractionation","year":"2024"},{"key":"10.1016\/j.radi.2026.103357_bib9","series-title":"Stereotactic ablative body radiation therapy (SABR): a resource","year":"2019"},{"issue":"11","key":"10.1016\/j.radi.2026.103357_bib10","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radi.2026.103357_bib11","article-title":"Dose-intensified stereotactic ablative radiation for localized prostate cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.radi.2026.103357_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/0284186X.2023.2213443","article-title":"Increased toxicities associated with dose escalation of stereotactic body radiation therapy in prostate cancer: results from a phase I\/II study","volume":"62","author":"Hirata","year":"2023","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.radi.2026.103357_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2021.03.025","article-title":"A multi-institutional phase 2 trial of high-dose SAbR for prostate cancer using rectal spacer","volume":"111","author":"Folkert","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.radi.2026.103357_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/13685538.2021.1948992","article-title":"The efficacy and tolerability of ultra-hypofractionated radiotherapy in low-intermediate risk prostate cancer patients: single centre experience","volume":"24","author":"Din\u00e7er","year":"2021","journal-title":"Aging Male"},{"issue":"10196","key":"10.1016\/j.radi.2026.103357_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.radi.2026.103357_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ijrobp.2016.11.008","article-title":"Acute and late adverse events associated with radical radiation therapy prostate cancer treatment: a systematic review of clinician and patient toxicity reporting in randomized controlled trials","volume":"97","author":"Holch","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.radi.2026.103357_bib17","first-page":"5","article-title":"Writing narrative literature reviews for peer-reviewed journals: secrets of the trade","volume":"15","author":"Green","year":"2001","journal-title":"J Sports Chiropr Rehabil"},{"issue":"5","key":"10.1016\/j.radi.2026.103357_bib18","first-page":"457","article-title":"Randomized controlled trial: the gold standard or an unobtainable fallacy?","volume":"37","author":"Bondemark","year":"2015","journal-title":"EJO (Eur J Orthod)"},{"key":"10.1016\/j.radi.2026.103357_bib19","article-title":"The impact of rectal spacers in MR-guided adaptive radiotherapy","volume":"49","author":"Batumalai","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"10.1016\/j.radi.2026.103357_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radi.2026.103357_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.radonc.2020.04.039","article-title":"Accelerating prostate stereotactic ablative body radiotherapy: efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)","volume":"149","author":"Alayed","year":"2020","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.radi.2026.103357_bib22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijrobp.2023.02.054","article-title":"A randomized feasibility trial of stereotactic prostate radiation therapy with or without elective nodal irradiation in high-risk localized prostate cancer (SPORT trial)","volume":"117","author":"Houlihan","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1084","key":"10.1016\/j.radi.2026.103357_bib23","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170625","article-title":"Safety and feasibility of prostate stereotactic ablative radiotherapy using multimodality imaging and flattening filter free","volume":"91","author":"Duffton","year":"2018","journal-title":"Br J Radiol"},{"issue":"6","key":"10.1016\/j.radi.2026.103357_bib24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.euo.2019.09.006","article-title":"Early tolerance and tumor control outcomes with high-dose ultrahypofractionated radiation therapy for prostate cancer","volume":"3","author":"Zelefsky","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.radi.2026.103357_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13014-019-1346-5","article-title":"Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes","volume":"14","author":"Hwang","year":"2019","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.radi.2026.103357_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13014-019-1369-y","article-title":"A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer","volume":"14","author":"Kainuma","year":"2019","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.radi.2026.103357_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13014-021-01834-1","article-title":"Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison","volume":"16","author":"Ogita","year":"2021","journal-title":"Radiat Oncol"},{"issue":"6","key":"10.1016\/j.radi.2026.103357_bib28","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-018-1155-y","article-title":"\u201cGive me five\u201d ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach","volume":"35","author":"Marvaso","year":"2018","journal-title":"Med Oncol"},{"issue":"4","key":"10.1016\/j.radi.2026.103357_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11547-023-01618-5","article-title":"Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial","volume":"128","author":"Gregucci","year":"2023","journal-title":"La radiologia medica"},{"issue":"2","key":"10.1016\/j.radi.2026.103357_bib30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00066-018-1338-7","article-title":"Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer","volume":"195","author":"Alongi","year":"2019","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"10.1016\/j.radi.2026.103357_bib31","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.21873\/anticanres.15733","article-title":"Acute side-effects of different radiotherapy treatment schedules in early prostate cancer","volume":"42","author":"Reinikainen","year":"2022","journal-title":"Anticancer research"},{"key":"10.1016\/j.radi.2026.103357_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1143716","article-title":"Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: results of a single-arm monocenter Phase-II trial","volume":"13","author":"Nguyen","year":"2023","journal-title":"Frontiers in oncology"},{"key":"10.1016\/j.radi.2026.103357_bib33","article-title":"Acute toxicity patterns and their management after moderate and ultra-hypofractionated radiotherapy for prostate cancer: a prospective cohort study","volume":"48","author":"Sinzabakira","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1093","key":"10.1016\/j.radi.2026.103357_bib34","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20189005","article-title":"Pushing the frontiers of radiobiology: a special feature in memory of sir oliver scott and professor jack fowler","volume":"92","author":"Martin","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radi.2026.103357_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.phro.2018.05.001","article-title":"The effect of prostate motion during hypofractionated radiotherapy can be reduced by using flattening filter free beams","volume":"6","author":"Benedek","year":"2018","journal-title":"Physics and imaging in radiation oncology"},{"issue":"4","key":"10.1016\/j.radi.2026.103357_bib36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4300\/JGME-D-22-00480.1","article-title":"Narrative reviews: flexible, rigorous, and practical","volume":"14","author":"Sukhera","year":"2022","journal-title":"Journal of graduate medical education"},{"issue":"2","key":"10.1016\/j.radi.2026.103357_bib37","first-page":"69","article-title":"SABR vs. SBRT: a new deal for radiotherapy beyond terminology","volume":"IV","author":"Montero","year":"2024","journal-title":"JMRO"}],"container-title":["Radiography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078817426000337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078817426000337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:35:46Z","timestamp":1781739346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078817426000337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1078817426000337"],"URL":"https:\/\/doi.org\/10.1016\/j.radi.2026.103357","relation":{},"ISSN":["1078-8174"],"issn-type":[{"value":"1078-8174","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimising on-treatment review schedules: A narrative review of acute toxicities in ultra-hypofractionated stereotactic ablative body radiotherapy (SABR) for localised prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Radiography","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radi.2026.103357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of The College of Radiographers.","name":"copyright","label":"Copyright"}],"article-number":"103357"}}